News for Arrowhead Pharmaceuticals, Inc. (0HI3.L)

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced on July 22, 2025, that its Board of Directors has approved inducement grants for 38 new employees. These

Arrowhead Pharmaceuticals (ARWR) is poised for financial growth despite recent industry shifts affecting its partner, Sarepta Therapeutics (SRPT). The company i

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss it

Arrowhead Pharmaceuticals (ARWR) to webcast Q3 2025 results on August 7, at 4:30 p.m. ET. Webcast access through Arrowhead's Investors section, with rep

Arrowhead Pharmaceuticals, trading under the ticker ARWR, saw its stock fall by 8.9%, a decrease of $1.49, landing at a price of $15.28. This drop comes as inve

Arrowhead Pharmaceuticals (ARWR) has successfully completed participant enrollment for its global Phase 3 clinical trials, named SHASTA-3, SHASTA-4, and MUIR-3.

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced the completion of enrollment for its SHASTA-3, SHASTA-4, and MUIR-3 global Phase 3 clinical studies, aime

We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: “You know, look, it doesn’t make any […]

Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) therapeutic targeting adipose-specific gene expression to combat obesity.

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced on [date] the commencement of a Phase 1/2a clinical trial for ARO-ALK7, an investigational RNA interferen

Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for its experimental RNA interference therapy, ARO-ALK7, aimed at addressing obesity. Design

Arrowhead Pharmaceuticals (ARWR) has begun a Phase 1/2a trial for its RNAi therapeutic, ARO-ALK7, targeting obesity treatment. ARO-ALK7 aims to silence the

Summary Arrowhead Pharmaceuticals Inc (ARWR), a company specializing in RNA interference-based therapeutics, announced its participation in two significant inve

Arrowhead Pharmaceuticals (ARWR) to participate in two major investor conferences in June 2025. Engagements include Jefferies Global Healthcare Conferen

UBS has revised its price target for Arrowhead (ARWR), decreasing it from $71 to $63. Despite this adjustment, the firm maintains its Buy rating on the stock, i

Arrowhead Pharmaceuticals (ARWR) finds itself in the spotlight as Citigroup analyst Shawn Egan has adjusted the company's stock price target while maintaining a

Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS...